Skip to main content
. 2024 Apr 3;26:e53375. doi: 10.2196/53375

Table 1.

Summary of topics with representative paraphrased posts (N=36,424).

Topic number and label Top 10 words by frequency Topic proportion (% of tokens) Posts, n (%) Valence, mean (SD) Representative paraphrased posts
Topic 1: HIV and COVID-19

  • Vaccine

  • HIV

  • Use

  • Covid

  • Aids

  • Year

  • Get

  • People

  • Test

  • Make

 77.9 33,678 (92.46) 0.055 (0.480)

  • It’s astonishing that some people are opposed to vaccinations, when COVID vaccines have paved the way for HIV vaccine trials. (January 29, 2022; topic-specific loading: 0.862; likes: 30,591; reposts: 370)

  • Let me clarify. A small portion of the HIV virus was added in the Covid vaccine as to stabilize the protein. This vaccine was given to people. Now, a year later, they are indicating a rise in HIV cases, urging people to get HIV tests while developing an HIV vaccine. (February 8, 2022; topic-specific loading: 0.807; likes: 3207; reposts: 1456)
Topic 2: mRNAa HIV vaccine trials

  • Trial

  • mRNA

  • Moderna

  • Technology

  • Clinical

  • Begin

  • Experimental

  • First

  • Launch

  • News

 14.4 2151 (5.91) 0.040 (0.363)

  • I am thrilled to share exciting news. The first patient has received a dose in the phase 1 trial of Moderna’s mRNA-1644, an HIV vaccine candidate, which utilizes the same mRNA technology as our COVID-19 vaccines! (January 27, 2022; topic-specific loading: 0.521; likes: 18,895; reposts: 881)

  • I have some exciting news to share. The first patient has received a dose in the phase 1 trial of Moderna’s and National Institutes of Health HIV trimer vaccine candidate, mRNA-1574, which utilizes the same mRNA technology as our COVID-19 vaccines! (March 21, 2022; topic-specific loading: 0.585; likes: 7056; reposts: 1224)
Topic 3: HIV vaccine and immunity

  • Response

  • Immune

  • Risk

  • Protein

  • Antibody

  • Immunity

  • Spike_protein

  • High

  • Add

  • GT

 7.8 595 (1.63) −0.008 (0.445)

  • New study: Analyzing two cooperating antibodies reveals immune pressure on HIV Env to elicit a V3-glycan supersite broadly neutralizing antibody lineage. The goal of vaccine is to stimulate broadly neutralizing antibodies. (September 26, 2022; topic-specific loading: 0.602; likes: 11; reposts: 4)

  • QTNSPRRAR is the t-cell CD8 activator essential in establishing a durable t-cell response to ACE2 receptor binding. This creates a sustained t-cell response to binding and then the antibody response to HIV like proteins, which is like all other t-cell vaccine adjuvants. (April 25, 2022; topic-specific loading: 0.506; likes: 12; reposts: 1)

amRNA: messenger RNA.